CHMP Gave Positive Opinions To Update The Composition Of The Moderna's MRNA Vaccine Spikevax1, To Target SARS-COV-2 JN.1 Variant Of The Virus That Causes Covid-19
Portfolio Pulse from Benzinga Newsdesk
The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on updating the composition of Moderna's mRNA vaccine, Spikevax, to target the SARS-COV-2 JN.1 variant. This development is significant for Moderna as it enhances the vaccine's effectiveness against new virus strains.
September 20, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna received a positive opinion from CHMP to update its Spikevax vaccine to target the SARS-COV-2 JN.1 variant. This regulatory approval is likely to enhance the vaccine's marketability and effectiveness.
The CHMP's positive opinion is a crucial regulatory step that allows Moderna to update its vaccine, potentially increasing its demand and market share as it becomes more effective against new variants.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100